Adapalene: Pharmacological and therapeutic features;Adapalene: Profilo farmacologico e terapeutico

Giornale Italiano di Dermatologia e Venereologia

Volumn 138, Issue 1, 2003, Pages 49-56

  Cassano, N ^a   Alessandrini, G ^c   Carrieri, G ^c   Fai, D ^c   Gabbellone, M ^c   Gravante, M ^c   Ligori, P ^c   Mancino, A ^c   Manco, S ^c   Martina, G ^c   Nataliziti, A ^c   Sodo, M R ^c   Stasi, R ^c   Vena, G A ^a,b  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

^c Dipartimento di Clinica Medica Sezione di Dermatologia Policlinico Piazza Giulio Cesare ^*

Author keywords

Acne vulgaris; Administration and dosage Retinoids; Pharmacology; Therapeutic use Retinoids; Therapy Retinoids

Indexed keywords

ADAPALENE; CLINDAMYCIN PHOSPHATE; DRUG RECEPTOR; ERYTHROMYCIN; RETINOIC ACID;

ACNE VULGARIS; ANTIINFLAMMATORY ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CREAM; CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PREFERENCE; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TOLERABILITY; ERYTHEMA; GEL; HUMAN; LIPOPHILICITY; MELTING POINT; NONHUMAN; PATIENT COMPLIANCE; PHOTOALLERGY; QUALITY OF LIFE; REVIEW; SEBACEOUS GLAND; SIDE EFFECT;

EID: 0037544215     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Weiss JS, Shavin JS. Adapalene for the treatment of acne vulgaris. J Am Acad Dermatol 1998;39:S50-4.
2. Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 1998;39:S17-24.
3. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998;139 Suppl 52:8-11.
4. Apfel C, Crettaz M, Siegenthaler G, Hunziker W. In: Saurat J-H, editor. Synthetic retinoids: differential binding to retinoid acid receptors. Retinoids 10 years on. Basel: Karger; 1991.p.110-20.
5. Chen S, Darling IM, Yu K-L, Starrett JE, Mansuri MM, Whiting G et al. In vivo activity of retinoid esters in skin is related to in vitro hydrolysis rate. J Pharm Pharmacol 1995;47:626-31.
6. Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol 1997;36:S119-25.
7. Jamoulle JC, Grandjean L, Lamaud E, Shroot B, Schaefer BH. Follicular penetration and distribution of topically applied CD 271, a new naphthoic acid derivative intended for topical acne treatment. J Invest Dermatol 1990;94:731-2.
8. Cunliffe WJ. A new topical retinoid - why a new topical acne therapy? Br J Dermatol 1998;139 Suppl 52:1-2.
9. Verschoore M, Langner A, Wolska H, Jablonska S, Czernielewski J, Schaefer H. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol 1991;124:368-71.
10. Shalita A, Weiss JS, Chalker DK, Ellis CN, Greenspan A, Katz HI et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996;34:482-5.
11. Alirezai M, Meynadier J, Jablonska S, Czernielewski J, Verschoore M. Étude comparative de efficacité et de tolérance de gels d'adapalène à 0.1 et 0.03 p. 100 et d'un gel de trétinoïne à 0.025 p.100 dans le traitement de l'acné. Ann Dermatol Venereol 1996;123:165-70.
12. Brogden RN, Goa KL. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997;53:511-9.
13. nd ed. London: Martin Dunitz; 1998.p.9-19.
14. Chandraratna R, Klein ES. Retinoid nuclear receptors. In: Lowe N, Marks R, editors. Retinoids. A clinician's guide. 2nd Ed. London: Martin Dunitz; 1998.p.21-32.
15. Masouyé I, Gaub MP, Rochette-Egly C, Didierjean L, Chambon P, Saurat JH. Distribution of retinoic acid receptors alpha1 and gamma1 in human epidermis, oral mucosa and psoriasis. J Invest Dermatol 1992;98:534.
16. Bernard BA. Adapalene, a new chemical entity with retinoid activity. Skin Pharmacol 1993;6 Suppl 1:61-9.
17. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997;36:S96-103.
18. Griffiths CE, Elder JT, Bernard BA, Rossio P, Cromie MA, Finkel LJ et al. Comparison of CD271 (adapalene) and all-trans retinoic acid in human skin: dissociation of epidermal effects and CRABP-II mRNA expression. J Invest Dermatol 1993;101:325-8.
19. Griffiths CE, Ancian P, Humphries J, Poncet M, Rizova E, Michel S et al. Adapalene 0.1% gel and adapalene 0.1% cream stimulate retinoic acid receptor mediated gene transcription without significant irritative effects in the skin of healthy human volunteers. Br J Dermatol 1998;139 Suppl 52:12-6.
20. Hensby C, Cavey D, Bouclier M, Chatelus A, Algate D, Eustache J et al. The in vivo and in vitro anti-inflammatory activity of CD271: a new retinoid-like modulator of cell differentiation. Agents Actions 1990;29:56-8.
21. Bernerd F, Ortonne JP, Bouclier M, Chatelus A, Hensby C. The rhino mouse model: the effects of topically applied all-trans retinoic acid and CD271 on the fine structure of the epidermis and utricle wall of pseudocomedones. Arch Dermatol Res 1991;283:100-7.
22. Bouclier M, Chatelus A, Ferracin J, Delain C, Shroot B, Hensby CN. Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standardized image analysis technique. Skin Pharmacol 1991;4:65-73.
23. Asselineau D, Cavey MT, Shroot B, Darmon M. Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP). J Invest Dermatol 1992;98: 128-34.
24. Michel S, Jomard A, Démarchez M. Pharmacology of adapalene. Br J Dermatol 1998;139 Suppl 52:3-7.
25. Altomare G, Capella GL, Fracchiolla C, Frigerio E. Effectiveness of topical adapalene in Dowling-Degos disease. Dermatology 1999;198: 176-7.
26. English JC 3rd, Browne J, Halbach DP. Effective treatment of localized Darier's disease with adapalene 0.1% gel. Cutis 1999;63: 227-30.
27. Caron D, Sorba V, Clucas A, Verschoore M. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol 1997;36:S113-5.
28. Cunliffe WJ, Caputo R, Dreno B, Förstrom L, Heenen M, Orfanos CE et al. Efficacy and safety comparison of adapalene (CD271) gel and tretinoin gel in the topical treatment of acne vulgaris: a European multicentre trial. J Dermatol Treat 1997;8:173-8.
29. Caron D, Sorba V, Kerrouche N, Clucas A. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997;36:S110-2.
30. Cunliffe WJ, Caputo R, Dreno B, Förstrom L, Heenen M, Orfanos CE et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol 1997;36:S126-34.
31. Grosshans E, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998;139 Suppl 52:26-33.
32. Cunliffe WJ, Poncet M, Loesche C, Versschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998;139 Suppl 52:48-56.
33. Piérard-Franchimont C, Henry F, Fraiture AL, Fumal I, Piérard GE. Split-face clinical and bio-instrumental comparison of 0.1% adapalene and 0.05% tretinoin in facial acne. Dermatology 1999;198:218-22.
34. Meynadier J, Cunliffe WJ, Danby W, Dunlap F, Gold MH, Gratton D et al. Etude comparative de la tolérance et de l'efficacité du gel d'adapalène à 0.1% et de la crème de Trétinoine à 0.05% dans l'acné. Ann Dermatol Venereol 2000;127 Suppl 4:S77-227.
35. Clucas A, Verschoore M, Sorba V, Poncet M, Baker M, Czernielewski J. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997;36:S116-8.
36. Toole JW, Lockhart L, Potrebka J, Bowman JP, Novack GD. Comparative irritancy study among retinoid creams and gels. J Cutan Med Surg 1999;3:298-301.
37. Verschoore M, Poncet M, Czernielewski J, Sorba V, Clucas A. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol 1997;36:S104-9.
38. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998;139 Suppl 52:34-40.
39. Dunlap FE, Baker MD, Plott RT, Verschoore M. Adapalene 0.1% gel has low skin irritation potential even when applied immediately after washing. Br J Dermatol 1998;139 Suppl 52:23-5.
40. Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998;139 Suppl 52:17-22.